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Transfusion Practices Among Children Admitted to a South African PICU Following 
Cardiac Surgery  
Objective- We aimed to describe the use of blood products following cardiac surgery, as well 
as the outcomes and factors associated with post-operative blood product use 
Design- Prospective, single centre observational study 
Setting- Paediatric intensive care unit (PICU) in Cape Town, South Africa  
Patients- One hundred and twenty-six children <18 years old admitted to the PICU following 
cardiac surgery between July 2017 and January 2018 
Interventions- None 
Measurements and Main Results- The data was prospectively obtained from blood bank 
charts, intraoperative and PICU observation charts. Demographic data, intraoperative details 
and post-operative blood product use were extracted from patient records and entered in a 
standardised case record form. Fifty three percent of children received blood products 
following cardiac surgery. The blood products transfused included cryoprecipitate (30.9%), 
packed red cells (22.2%), albumin (18.3%), fresh frozen plasma FFP (15.9%) and platelet 
concentrate (15.1%). Low haemoglobin level was commonest indication (86%) for red cell use. 
Bleeding was the commonest indication for FFP (70%) and cryoprecipitate (67%) use. 
Thrombocytopenia was the commonest indication (84%) for platelet use while hypotension 
episodes were predominant (95%) in those who received albumin. The standardized mortality 
ratio was 3.1 vs 0, respectively, among transfused versus non-transfused patients (p<0.0001). 
The median (IQR) duration of PICU stay was 5 (3-11) vs 2 (2-5) days, respectively in those 
transfused versus non-transfused (p <0.0001). The median (IQR) ventilation duration was 47 
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(22-132) hours vs 20 (6-27) hours, respectively among the transfused versus non-transfused 
(p= < 0.0001). The factors associated with blood-product use post cardiac surgery include 
previous cardiac surgery, younger age, lower weights, and prolonged coagulation parameters 
(p= < 0.05).   
Conclusion- There is high usage of blood products among children post cardiac surgery. The 
children transfused had a longer ICU stay, ventilation duration, and higher standardized 
mortality ratio compared to the non-transfused. 
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Chapter 1: Introduction 
1.1 Context 
Blood products are not identical across the world and may vary considerably in how they are 
collected, stored, processed and administered. The quality of blood products is hugely variable 
in various parts of the world. The guidelines for blood transfusion in the cardiac perioperative 
period are based on relatively small numbers of studies, and the focus of this study was to 
define the transfusion practice in our unit.  This would provide the basis for further focus on 
quality improvement and optimization of protocols. 
Risk Factors Associated With Transfusion Or Bleeding During and After Cardiac 
Surgery 
The factors that predispose patients undergoing cardiac surgery to bleeding include patient, 
procedure and drug-related factors. Patient related factors include age, preoperative anaemia, 
preoperative thrombocytopenia, preoperative coagulopathy and antithrombotic therapy. 
Procedure related factors include repeated procedures (re-operation), the type and urgency of 
the operation, cardiopulmonary bypass (CPB); the use of heparin on CPB, residual heparin, 
reduced thrombin generation, fibrinogen deficiency, thrombocytopenia, platelet dysfunction, 
hyperfibrinolysis, hypothermia, acidosis during the procedure, dilution of clotting factors with 
intravenous fluid administration, surgical causes and consumption of clotting factors in active 
bleeding (1-3). 
Drug related factors are related to use of antiplatelet agents such as aspirin, clopidogrel or use 
of anticoagulant therapy such as warfarin, or use of low molecular weight heparin or 
unfractionated heparin (3). 
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The interventions that have been shown to reduce bleeding during cardiac surgery include: 
anti-fibrinolytic therapy such as tranexamic acid, recombinant factor VIIa and epsilon 
aminocaproic acid, use of minimized CPB circuits with reduced priming volume, 
normovolaemic haemodilution, salvage of blood from the CPB circuit, modified ultrafiltration, 
and microplegia (4-7). The use of pre-operative erythropoietin increases the haemoglobin level 
prior to surgery, hence reducing blood transfusion requirement. 
Type of Blood Products Used and Indications during Cardiac Surgery 
The use of haemoglobin level in isolation, as a threshold for red cell transfusion is not 
sufficient, and additional factors such as markers of oxygen delivery, ongoing bleeding and 
cormobid disease processes should be considerations factored in the decision to transfuse red 
blood cells (8). 
Red blood cells increase arterial oxygen content by increasing haemoglobin level, therefore 
increasing tissue oxygen delivery. However, this does not take immediate effect as red cell 
transfusion increases blood viscosity which can reduce cardiac output in normovolaemic 
patients whose cardiac function is not impaired. Stored red cells undergo biochemical and 
biophysiologic changes which affects their oxygen affinity and delivery (9). 
Fresh frozen plasma is a source of procoagulant factors and fibrinogen, and is indicated in the 
context of massive bleeding, where it is administered in fixed ratios with platelets and red cells 
(10, 11). Cryoprecipitate contains high concentrations of factors VIII,XIII and fibrinogen, and 
is indicated for correcting fibrinogen levels below 1g/l (12). 
Platelet transfusion is indicated in significant microvascular bleeding with diffuse oozing 
without an obvious surgical cause, after correction of clotting factors (1, 13). Platelet 
dysfunction and thrombocytopaenia increase the risk of bleeding and threshhold for transfusion 
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after CPB(14). The factors that influence platelet count and function during CPB include 
exposure to the bypass circuit and shear stress at different levels of CPB resulting in platelet 
adhesion and aggregation, inflammatory mediators during CPB, haemodilution, hypothermia, 
preoperative use of anti-platelet agents (1, 3, 15, 16). Other molecular mechanisms that 
contribute to platelet dysfunction include loss of cell surface glycoprotein receptors, such as 
the platelet collagen receptor, glycoprotein GPIb-IX and GPIIb-IIIa (1, 14).  
Transfusion Practice and Threshholds Used in Paediatric Cardiac Critical Care 
The physiologic threshold at which oxygen consumption decreases due to reduced oxygen 
delivery in humans is a haemoglobin level of 3-4 g/dl, an oxygen extraction ratio of 0.44 and 
a mixed venous oxygen of 34 mmHg as demonstrated in studies in Jehovah’s witness 
population who decline blood transfusion (17). The evidence guiding red cell transfusion 
threshholds in children is scanty. Data obtained from retrospective studies in Kenyan children 
with severe anemia related to high parasitemia from P.Falciparum malaria demonstrated high 
early mortality rates at haemoglobin levels below 4g/dl (18). Carson and colleagues 
demonstrated a > 50% mortality rate of  in patients with a post operative haemoglobin below 
levels of 5 g/dl, as well as a two-fold increase in odds of death for every 1g/dl drop in 
haemoglobin among adults with post-operative haemoglobin concentration below 8g/dl (19).  
Patients with ongoing bleeding, who are in haemorrhagic shock should receive red blood cells, 
with plasma and platelet concentrate in fixed ratios (8). Results from the subanalysis of the 
Transfusion Requirements in Paediatric Intensive Care Unit (TRIPICU) study suggest that a 
haemoglobin threshhold of 7g/dl  and 9 g/dl for haemodynamically stable children >28 days 
old with non cyanotic heart disease and  cyanotic heart disease respectively  is reasonable. 
These threshholds have been adapted for use in children post cardiac surgery (4, 8, 20). 
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The British Committee for standards in haematology recommends that fresh frozen plasma 
(FFP) and cryoprecipitate should not be used primarily on the basis of abnormal lab results, 
but should be restricted to use in patients with signs of bleeding or planned invasive procedures 
(21). FFP should be given to children with prothrombin time/ activated partial thromboplastin 
time (PT/APTT) levels >1.5 times the midpoint of the normal range and cryoprecipitate for 
fibrinogen levels <1.5g/l associated with significant haemorrhage following cardiopulmonary 
bypass (21). Platelets should be transfused when there is clinically significant haemorrage and 
a threshold of < 100*10⁹/l should be used in paediatric cardiac surgery (21). 
Complications Associated With Blood Product Use 
Blood product transfusion is associated with immune-mediated and non immune-mediated 
risks. Immune-mediated risks include transfusion-related lung injury, acute haemolytic 
reactions, allergic and anaphylactic reactions, non haemolytic febrile reactions, and transfusion 
associated graft versus host disease (2, 22). Non-immune mediated risks of blood transfusion 
include hyperkalaemia, fluid overload, transmission of infection, hypothermia and iron 
overload (22). 
The presence of leucocytes in blood has been linked to the febrile reactions and immune-
mediated reactions observed after blood transfusion, therefore leucoreduction and filtration is 
perfomed in most centres prior to blood storage (23-25). Leukoreduction has been further 
shown to increase packed red cell viability prior to storage (23). Although transfusion-
associated graft versus host disease (TA-GVHD) is an uncommon complication of blood 
transfusion, it is a fatal complication especially for patients with congenital immune deficiency, 
therefore gamma-irradiation of blood products prior to transfusion impairs the proliferation of 
lymphocytes, and prevents TA-GVHD (23, 25). 
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High income countries which are also quite well resourced, have adopted a universal policy of 
leucocyte depletion of stored blood products, which is a costly affair that low and middle-
income countries may not afford routinely. In South Africa, infants routinely receive 
leucodepleted bood as a standard, and the blood packs are leucodepleted during preparation 
and storage. Adult units are generally used to prime the bypass circuit for infants undergoing 
cardiac surgery. The adult blood packs are not routinely leucodepleted, unless there is a clinical 
indication to warrant the use of leucocyte depleted blood products, in this case the clinician 
will put in a specific request to the blood bank for leucocyte depleted blood (26, 27).  
Bacterial infections that occur post transfusion may happen because of bacterial contamination 
of blood products during venipuncture or collection of blood from an asymptomatic bacteremic 
donor. Gram negative bacteria such as Yersinia entercolitica and Pseudomonas rapidly 
proliferate at storage temperatures of 4°C, whereas gram positive bacteria such as 
Staphylococcus epidermidis, Staphylococcus aureus and Bacillus species proliferate rapidly at 
room temperature (22).  
In the well-resourced countries, donor blood is routinely screened for hepatitis B and C, human 
immunodeficient virus (HIV) 1 and 2, cytomegalovirus (CMV), human T cell lymphotropic 
virus and syphillis, and the incidence of viral transmission through blood transfusion has 
greatly reduced (22, 24, 28). In South Africa, donor blood is routinely screened for hepatitis B 
and C, HIV 1 and 2, and Syphillis. (South African National Blood Service) The variant 
Creudzfeldt-Jakob disease is a human prion disease that can also be transmitted by 
contaminated blood products (22, 28). The following are agents that can also be transmitted by 
transmission of contaminated blood, however they are not routinely screened in donor blood; 
hepatitis A virus, parvo B19 virus, Babesia leishmania, plasmodium, and Brucella species (28). 
Transfusion of blood products (red cells, fresh frozen plasma, platelet concentrate) intra and 
post operatively has also been found to be a potential risk factor to development of health care 
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associated infections in cardiac surgery (29-31). 
Several studies have been done and demonstrated an association between red cell transfusion 
and length of stay in post-operative paediatric cardiac patients (32-35). The use of lower 
haemoglobin thresholds for red cells transfusion and leucocyte reduced blood products are 
factors that have been shown to reduce morbidity related to paediatric cardiac surgery (36, 37). 
Transfusion-mediated immune suppression has been described in transfusion medicine and 
thought to pose an increased risk in postoperative infections and activation of latent viral 
infections (22, 24, 38). 
Complications such as transfusion related lung injury (TRALI), transfusion- associated cardiac 
overload, nosocomial infections, multi-organ organ dysfunction will result in increased 
ventilator days and hence increased ICU length of stay and have also been in implicated in 





1.Hartmann M, Sucker C, Boehm O, Koch A, Loer S, Zacharowski K. Effects of cardiac surgery on 
hemostasis. Transfusion medicine reviews. 2006;20(3):230-41. 
2.Despotis G, Eby C, Lublin DM. A review of transfusion risks and optimal management of 
perioperative bleeding with cardiac surgery. Transfusion. 2008;48(s1):2S-30S. 
3.Ranucci M. Hemostatic and thrombotic issues in cardiac surgery. Semin Thromb Hemost. 
2015;41(1):84-90. 
4.Ferraris VA, Brown JR, Despotis GJ, Hammon JW, Reece TB, Saha SP, et al. 2011 update to the 
Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation 
clinical practice guidelines. The Annals of thoracic surgery. 2011;91(3):944-82. 
5.Chauhan S, Bisoi A, Modi R, Gharde P, Rajesh M. Tranexamic acid in paediatric cardiac surgery. 
Indian Journal of Medical Research. 2003;118:86-9. 
6.Henry DA, Carless PA, Moxey AJ, O'Connell D, Stokes BJ, McClelland B, et al. Anti-fibrinolytic 
use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev. 
2007(4):Cd001886. 
7.Cholette JM, Powers KS, Alfieris GM, Angona R, Henrichs KF, Masel D, et al. Transfusion of cell 
saver salvaged blood in neonates and infants undergoing open heart surgery significantly reduces 
RBC and coagulant product transfusions and donor exposures: results of a prospective, randomized, 
clinical trial. Pediatr Crit Care Med. 2013;14(2):137-47. 
8.Lacroix J, Tucci M, Du Pont-Thibodeau G. Red blood cell transfusion decision making in critically 
ill children. Curr Opin Pediatr. 2015;27(3):286-91. 
9.Remy KE, Natanson C, Klein HG. The influence of the storage lesion(s) on pediatric red cell 
transfusion. Curr Opin Pediatr. 2015;27(3):277-85. 
10.Karam O, Tucci M. Massive Transfusion in Children. Transfus Med Rev. 2016;30(4):213-6. 
11.Karam O, Demaret P, Shefler A, Leteurtre S, Spinella PC, Stanworth SJ, et al. Indications and 
Effects of Plasma Transfusions in Critically Ill Children. Am J Respir Crit Care Med. 
2015;191(12):1395-402. 
12.Parker RI. Transfusion in Critically Ill Children: Indications, Risks, and Challenges. Critical Care 
Medicine. 2014;42(3):675-90. 
13.Guidelines for the use of platelet transfusions. Br J Haematol. 2003;122(1):10-23. 
14.Zubair MM, Bailly DK, Lantz G, Sunstrom RE, Saharan S, Boshkov LK, et al. Preoperative 
platelet dysfunction predicts blood product transfusion in children undergoing cardiac surgery. 
Interactive Cardiovascular and Thoracic Surgery. 2015;20(1):24-30. 
15.Romlin BS, Soderlund F, Wahlander H, Nilsson B, Baghaei F, Jeppsson A. Platelet count and 
function in paediatric cardiac surgery: a prospective observational study. British Journal of 
Anaesthesia. 2014;113(5):847-54. 
16.Nakayama Y, Nakajima Y, Tanaka K, Sessler D, Maeda S, Iida J, et al. Thromboelastometry-
guided intraoperative haemostatic management reduces bleeding and red cell transfusion after 
paediatric cardiac surgery. British journal of anaesthesia. 2015;114(1):91-102. 
17.Ott DA, Cooley DA. Cardiovascular surgery in Jehovah's Witnesses. Report of 542 operations 
without blood transfusion. Jama. 1977;238(12):1256-8. 
18.English M, Ahmed M, Ngando C, Berkley J, Ross A. Blood transfusion for severe anaemia in 
children in a Kenyan hospital. Lancet. 2002;359(9305):494-5. 
19.Carson JL, Noveck H, Berlin JA, Gould SA. Mortality and morbidity in patients with very low 
postoperative Hb levels who decline blood transfusion. Transfusion. 2002;42(7):812-8. 
20.Lacroix J, Hebert PC, Hutchison JS, Hume HA, Tucci M, Ducruet T, et al. Transfusion strategies 
for patients in pediatric intensive care units. N Engl J Med. 2007;356(16):1609-19. 
21.New HV, Berryman J, Bolton‐Maggs PH, Cantwell C, Chalmers EA, Davies T, et al. Guidelines 
on transfusion for fetuses, neonates and older children. British journal of haematology. 
2016;175(5):784-828. 
22.Maxwell MJ, Wilson MJA. Complications of blood transfusion. Continuing Education in 
Anaesthesia, Critical Care & Pain. 2006;6(6):225-9. 
23.Guzzetta NA. Benefits and risks of red blood cell transfusion in pediatric patients undergoing 
cardiac surgery. Pediatric Anesthesia. 2011;21(5):504-11. 
17 
 
24.Lavoie J. Blood transfusion risks and alternative strategies in pediatric patients. Pediatric 
Anesthesia. 2011;21(1):14-24. 
25.Kozek-Langenecker SA, Afshari A, Albaladejo P, Santullano CAA, De Robertis E, Filipescu DC, 
et al. Management of severe perioperative bleeding: guidelines from the European Society of 
Anaesthesiology. European Journal of Anaesthesiology (EJA). 2013;30(6):270-382. 
26.Blumberg N. Deleterious clinical effects of transfusion immunomodulation: proven beyond a 
reasonable doubt. Transfusion. 2005;45(2 Suppl):33S-9S; discussion 9S-40S. 
27.Bird A, Crookes R. Leucocyte depletion of blood components -- guidelines of the Blood 
Transfusion Services of South Africa. S Afr Med J. 2006;96(5):395-6. 
28.Vamvakas EC, Blajchman MA. Transfusion-related mortality: the ongoing risks of allogeneic 
blood transfusion and the available strategies for their prevention. Blood. 2009;113(15):3406-17. 
29.Turcotte RF, Brozovich A, Corda R, Demmer RT, Biagas KV, Mangino D, et al. Health care-
associated infections in children after cardiac surgery. Pediatr Cardiol. 2014;35(8):1448-55. 
30.Van der Wal J, van Heerde M, Markhorst DG, Kneyber MC. Transfusion of leukocyte-depleted 
red blood cells is not a risk factor for nosocomial infections in critically ill children. Pediatr Crit Care 
Med. 2011;12(5):519-24. 
31.Wylie MC, Graham DA, Potter-Bynoe G, Kleinman ME, Randolph AG, Costello JM, et al. Risk 
factors for central line-associated bloodstream infection in pediatric intensive care units. Infect 
Control Hosp Epidemiol. 2010;31(10):1049-56. 
32.Chohan S, McArdle F, McClelland D, Mackenzie S, Walsh T. Red cell transfusion practice 
following the transfusion requirements in critical care (TRICC) study: prospective observational 
cohort study in a large UK intensive care unit. Vox sanguinis. 2003;84(3):211-8. 
33.Willems A, Harrington K, Lacroix J, Biarent D, Joffe AR, Wensley D, et al. Comparison of two 
red-cell transfusion strategies after pediatric cardiac surgery: a subgroup analysis. Crit Care Med. 
2010;38(2):649-56. 
34.Hébert PC, Yetisir E, Martin C, Blajchman MA, Wells G, Marshall J, et al. Is a low transfusion 
threshold safe in critically ill patients with cardiovascular diseases? Critical care medicine. 
2001;29(9):S181-S8. 
35.Iyengar A, Scipione CN, Sheth P, Ohye RG, Riegger L, Bove EL, et al. Association of 
complications with blood transfusions in pediatric cardiac surgery patients. The Annals of thoracic 
surgery. 2013;96(3):910-6. 
36.Willems A, Harrington K, Lacroix J, Biarent D, Joffe AR, Wensley D, et al. Comparison of two 
red-cell transfusion strategies after pediatric cardiac surgery: a subgroup analysis. Critical care 
medicine. 2010;38(2):649-56. 
37.Rouette J, Trottier H, Ducruet T, Beaunoyer M, Lacroix J, Tucci M. Red blood cell transfusion 
threshold in postsurgical pediatric intensive care patients: a randomized clinical trial. Ann Surg. 
2010;251(3):421-7. 
38.Székely A, Cserép Z, Sápi E, Breuer T, Nagy CA, Vargha P, et al. Risks and predictors of blood 
transfusion in pediatric patients undergoing open heart operations. The Annals of thoracic surgery. 
2009;87(1):187-97. 
39.Willems A, Harrington K, Lacroix J, Biarent D, Joffe AR, Wensley D, et al. Comparison of two 
red-cell transfusion strategies after pediatric cardiac surgery: a subgroup analysis. Critical care 
medicine. 2010;38(2):649-56. 
40.Church GD, Matthay MA, Liu K, Milet M, Flori HR. Blood product transfusions and clinical 






1.2 Ethical Considerations 
 
Potential risks and benefits 
This was a minimal- risk observational study of routinely collected data related to standard 
clinical practice and no study- related interventions or investigations were performed.  
Patients did not directly benefit from study participation.The findings of this study will form 
the baseline for future studies and inform practice- improvement initiatives, which has a  
potential societal benefit for improved practice and outcomes for future children admitted for 
cardiac surgery. 
Ethical compliance 
The study was undertaken after approval from the  Department of Paediatrics and Child 
Departmental Research Committee (DRC) and the University of Cape Town’s Faculty of 
Health Sciences Human Research Ethics Committee (HREC ref: 437/2017), and carried out as 
guided by the Declaration of Helsinki, 2013, Ethical Principles for Medical Research involving 
Human Subjects (see appendices). Permission was also obtained from the hospital CEO before 
the study was commenced (see appendices). The investigators requested and obtained a waiver 
of the need for full informed consent due the non-interventional and minimal risk nature of this 
study. The information obtained from the study was kept confidential by recording data in 






Chapter 2: Publication-ready manuscript 
 
Transfusion Practices Among Children Admitted to a South African PICU Following 
Cardiac Surgery  
Kaiser Fitzwanga, MMED (Paediatrics), Cert.crit care (Paed)¹, Brenda Morrow, BSc 
(Physiotherapy), PG Dip(Health Res Ethics), PhD (Paediatrics)¹, Shamiel Salie, FC Paed 
(SA), Cert.crit care (Paed), MPH¹, Andrew Argent, FC Paed (SA), MD (Paediatrics), 
Cert.crit care (Paed), FRCPCH (UK)¹ 
¹Department of Paediatrics, University of Cape Town, South Africa 
Objective- We aimed to describe the use of blood products following cardiac surgery, as well 
as the outcomes and factors associated with post-operative blood product use 
Design- Prospective, single centre observational study 
Setting- Paediatric intensive care unit (PICU) in Cape Town, South Africa  
Patients- One hundred and twenty-six children <18 years old admitted to the PICU following 
cardiac surgery between July 2017 and January 2018 
Interventions- None 
Measurements and Main Results- The data was prospectively obtained from blood bank 
charts, intraoperative and PICU observation charts. Demographic data, intraoperative details 
and post-operative blood product use were extracted from patient records and entered in a 
standardised case record form. Fifty three percent of children received blood products 
following cardiac surgery. The blood products transfused included cryoprecipitate (30.9%), 
packed red cells (22.2%), albumin (18.3%), fresh frozen plasma FFP (15.9%) and platelet 
concentrate (15.1%). Low haemoglobin level was commonest indication (86%) for red cell use. 
20 
 
Bleeding was the commonest indication for FFP (70%) and cryoprecipitate (67%) use. 
Thrombocytopenia was the commonest indication (84%) for platelet use while hypotension 
episodes were predominant (95%) in those who received albumin. The standardized mortality 
ratio was 3.1 vs 0, respectively, among transfused versus non-transfused patients (p<0.0001). 
The median (IQR) duration of PICU stay was 5 (3-11) vs 2 (2-5) days, respectively in those 
transfused versus non-transfused (p <0.0001). The median (IQR) ventilation duration was 47 
(22-132) hours vs 20 (6-27) hours, respectively among the transfused versus non-transfused 
(p= < 0.0001). The factors associated with blood-product use post cardiac surgery include 
previous cardiac surgery, younger age, lower weights, and prolonged coagulation parameters 
(p= < 0.05).   
Conclusion- There is high usage of blood products among children post cardiac surgery. The 
children transfused had a longer ICU stay, ventilation duration, and higher standardized 
mortality ratio compared to the non-transfused. 
Key words: blood product(s); transfusion; practice(s); children; cardiac surgery 
 
Introduction 
Blood products are frequently given to patients undergoing cardiac surgery. Recently, there has 
been increasing focus on the complications associated with blood transfusion.  Some of those 
complications relate primarily to the volumes of blood used, but many relate to the blood 
products themselves (1, 2). The initial focus of adverse event review was on issues such as 
compatibility, bacterial and increasingly viral infections. There is now increasing focus on the 
associations between use of blood products and respiratory problems, duration of PICU stay, 
morbidity and mortality (1, 2). Blood products are not identical across the world and may vary 
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considerably in how they are collected, stored, processed, administered and overall quality. 
The guidelines for blood transfusion in the cardiac perioperative period are based on relatively 
small numbers of studies, primarily from countries with high quality blood products. The 
primary objectives of this observational study were to describe the use of blood products and 
their indications during the 72-hour period following cardiac surgery. The secondary objectives 
were to describe the PICU mortality, PICU length of stay, duration of ventilation and the factors 
associated with post-operative blood use. 
Materials and Methods 
 
Study site 
This study was conducted in the intensive care unit of the Red Cross War Memorial Children’s 
Hospital, South Africa, which is a 22-bedded multi-disciplinary unit that serves the Western 
Cape province. It is a closed PICU which serves both medical and surgical specialties, and 
approximately 1300 admissions are recorded annually.  
Study Population 
We prospectively, consecutively recruited all children less than 18 years admitted to the PICU 
following cardiac surgery, during the period 13 July 2017 to 13 January 2018. Children 
admitted to PICU with medical and surgical conditions other than cardiac surgery were 
excluded from the study. 
Data Collection and Management 
The data was obtained from blood bank records, intra operative charts and patient folders 
(including PICU observation charts). The definition of blood products included the following; 
red blood cells, fresh frozen plasma (FFP), platelets, cryoprecipitate and human albumin. The 
information regarding the type and characteristics of the different blood products used was 
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obtained from the blood bank records. Chest drain losses was used as the surrogate marker for 
active bleeding, with losses ≥4ml/kg/hr considered as significant bleeding in our unit. Previous 
blood transfusion was defined as recent blood product administration within 14 days 
preceeding the current cardiac surgery. Hypotension episodes were defined as the systolic 
blood pressure or mean blood pressure below the low limit as set by the intensivist. 
The intra operative charts provided the following information: preoperative cardiac diagnosis, 
surgical procedure performed, the type and characteristics of the different blood products used, 
haemoglobin level pre and post surgery, details on cardiopulmonary bypass (CPB) and the use 
of pharmacotherapy (tranexamic acid, Vitamin K, activated factor VII) to prevent bleeding. 
Demographic data (age, sex, weight, date of PICU admission and discharge) was obtained from 
the patient folders. In addition, data regarding haemoglobin levels, oxygen saturations, 
hypotension episodes, clotting profile, chest drain losses, duration of mechanical ventilation, 
length of stay and mortality (including PIM 3 scores (3, 4)) in the PICU, previous cardiac 
surgery, previous blood transfusion, previous ICU admission was obtained from the patient 
folders and PICU observation charts.  
Data on the different blood products used intraoperatively and their characteristics was 
recorded. Details of the blood products used in the PICU, indications and volume (in ml/kg) of 
each blood product prescribed during the first 72 hours following cardiac surgery was recorded. 
Daily data collection captured the chest drain losses (in ml/kg/hr) during the first 72 hours 
following cardiac surgery. The outcomes recorded included length of stay in the PICU, total 
duration of ventilation and mortality. 
All the data obtained was filled into a standardised case record form before transfering it into 
an excel data base (Excel 2016). We requested and received a waiver of the need for full 
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informed consent from the parents/guardians of the study participants, owing to the low risk, 
observational study design.  
The study was undertaken after approval from the  Department of Paediatrics and Child 
Departmental Research Committee and the University of Cape Town’s Faculty of Health 
Sciences Human Research Ethics Committee (HREC 437/2017), and carried out as guided by 
the Declaration of Helsinki, 2013, Ethical Principles for Medical Research involving Human 
Subjects. We also obtained permission from the hospital medical superintendant before 
commencing the study. 
Statistical Analysis 
Descriptive statistics were tested for normality using the Shapiro Wilks W test, and the data 
are summarized using median (interquartile range) for continuous variables and n (%) for 
categorical variables. Inferential statistics were conducted with the primary and secondary 
outcomes of blood transfusion and mortality using Mann-Whitney u and Chi Square tests as 
appropriate. Continuous data were compared using Spearman rank order correlation tests. 
Variables found to be significantly associated with blood product use were entered into 
stepwise binary logistic regression models to determine independent predictive factors. Results 
were considered statistically significant when the p-value was less than 0.05. Statistical 






The characteristics of the 126 patients admitted to PICU following cardiac surgery are 
summarized in Table 1. Twenty-two (17.5%) patients had undergone previous cardiac surgery, 
of which 15.1% were median sternotomies. The commonest single lesion pre-operative cardiac 
diagnoses were: atrioventricular septal defect-17 (13.5%), tetralogy of fallot-12 (9.5%), 
ventricular septal defect-11 (8.7%), mitral regurgitation-7 (5.6%), aortic stenosis-6 (4.8%), 
total anomalous pulmonary venous connection- 6 (4.8%), patent ductus arteriosus- 6 (4.8%), 
atrial septal defect-5 (3.9%).  
The commonest single cardiac surgical repairs included: total correction of tetralogy of fallot-
13 (10.3%), ventricular septal defect repair-11 (8.7%), atrial septal defect repair-11 (8.7%), 
fontan operation-7 (5.6%), patent ductus ligation- 7 (5.6%), mitral valve repair-6 (4.8%), total 
anomalous pulmonary venous connection repair-6 (4.8%). The commonest two lesion cardiac 
surgical repair was atrial and ventricular septal defect repair-12 (9.5%).  
Sixty-nine patients admitted to the PICU had received pharmacotherapy to prevent bleeding in 
theatre, of which 68 patients received tranexamic acid and one patient received both tranexamic 
acid and activated factor VII. Six (4.8%) patients received pharmacotherapy to prevent 
bleeding in ICU, which included Vitamin K (33.3%), tranexamic acid (33.3%) and activated 
factor VII (33.3%). Sixty-eight (53.9%) patients received blood products in theatre, and 50% 
of the patients received red blood cells as a single blood product, followed by 25% who 
received red blood cells in combination with platelets and cryoprecipitate. The length of stay 
(LOS) was 5 (2-11) versus 3 (2-5) days (p=0.002) in those who received versus those who did 





Table 1: Characteristics of the study group 
Variable Total (N) Median IQR 
Weight (kg) 126 7.6 4.1-16.0 
Age (months) 126 14.3 3.8-66.4 
Risk of mortality (PIM 3) 126 0.01 0.01-0.02 
PICU duration (days) 126 3.5 2.0-7.0 
Haemoglobin post-surgery (g/dl) 126 10.4 9.3-12.2 
ACT pre-bypass (sec) 113 113.0 104.0-122.0 
ACT post-bypass (sec) 113 141.0 126.0-162.0 
Haemoglobin at PICU admission (g/dl) 126 12.7 11.1-14.2 
PTT at PICU admission (sec) 117 32.0 25.6-42.7 
Fibrinogen at PICU admission (g/L) 118 1.4 1.1-1.9 
Platelet count at PICU admission (*10⁹/L) 126 197.5 127.0-253.0 
Ventilation duration (hours) 112 23.6 17.5-90.5 
 
Variable Frequency (%) N=126 
Female 58 (46.0%) 
Previous cardiac surgery 22 (17.5%) 
Recent transfusion 4 (3.2%) 
Pharmacotherapy to prevent bleeding post-
surgery 
69 (54.8%) 
Blood product use during surgery 68(53.9%) 
Repeat cardiopulmonary bypass in theatre 14 (11.1%) 
Pharmacotherapy to prevent bleeding in PICU 6 (4.8%) 
Pre-operative cardiac diagnosis  
          1 lesion 83 (65.9%) 
          2 lesions 31 (24.6%) 
       ≥ 3 lesions 12 (9.5%) 
Cardiac surgical procedure  
          1 lesion repair 85 (67.5%) 
          2 lesion repairs 32 (25.4%) 
       ≥ 3 lesion repairs 9 (7.1%) 
 
The different blood products used during cardiac surgery are summarised in table 2 below. 
Sixty-eight (53.9%) patients received blood products intraoperatively, with packed red cells 
being the predominant single blood product received. Ten (7.9%) patients received a 
combination of two different blood products, nineteen (15.1%) patients received a combination 
of three different blood products and one (0.8%) patient received a combination of four 




Table 2: Blood products used in children during cardiac surgery in the OR 
Blood product Frequency (%, N=126) 
Packed red cells 34 (26.9%) 
Cryoprecipitate 3 (2.4%) 
Platelet concentrate 1 (0.8%) 
 
The different blood products and the median volumes used post cardiac surgery are summarised 
in Table 3. A total of 67 (53.2%) children received blood products in PICU following cardiac 
surgery. Cryoprecipitate was the commonest blood product used (30.9%) post cardiac surgery, 
followed by packed red cells (22.2%), 18.3% of the patients received albumin, 15.9% received 
FFPs and 15.1% were transfused platelet concentrate. There was an overlap of 41 (32.5%) 
patients, who received blood products in both the operating room and the PICU. 
Table 3: Blood products used in children post cardiac surgery in the PICU 
Blood product Frequency (%, N=126) Median volume transfused (ml/kg) 
Cryoprecipitate 39 (30.9%) 1.9 (IQR 1.6-3.0) 
Packed red cells  28 (22.2%) 16.1 (IQR 14.2-20.1) 
Albumin 23 (18.3%) 10.1 (IQR 5.2-22.2) 
Fresh frozen plasma 20 (15.9%) 12.1 (IQR 10.1- 17.6) 
Platelet concentrate 19 (15.1%) 14.2 (IQR 10.0-20.2) 
 
Table 4: Indications for blood product use in children post cardiac surgery 
The indications for the different blood products that were used have been summarised below. 
Blood product Indications for use 
1.Cryoprecipitate Bleeding (67%). Median chest drain loss threshold 4.5 ml/kg/hr (IQR 
2.3-5.9) 
 Low fibrinogen level (64%). Median fibrinogen level threshold 0.9g/l 
(IQR 0.7-1.1) 
 Hypotension episodes (23%) 
 Consultant orders (10%) 
2.Packed red cells Low haemoglobin level (86%). Median haemoglobin threshold 
7.9g/dl (IQR7.3-8.7) 
 Hypotension episodes (32%) 
 Bleeding (25%). Median chest drain loss threshold 8.5m/kg/hr (IQR 
5.9-18.0) 
 Consultant orders (25%) 
 
3.Albumin Hypotension episodes (95%) 




4.Fresh frozen plasma 
(FFP) 
Bleeding (70%). Median chest drain loss threshold 5.6 ml/kg/hr (IQR 
2.3-7.0) 
 Partial thromboplastin time level (45%); ≥ *2 control (35%) 
 Hypotension episodes (35%) 
 Consultant orders (25%) 
5.Platelet concentrate Thrombocytopenia (84%). Median platelet count threshold 67*10⁹/l 
(IQR 46.5-93.5) 
 Bleeding (63%). Median chest drain loss threshold 5.9 ml/kg/hr (IQR 
4.3-10.0) 
 Hypotension episodes (42%) 
 Consultant orders (10%) 
 
Other indications for blood product use following cardiac surgery included: during 
resuscitation in the presence of generalised oozing, oozing from the sternal wound and central 
line insertion site (packed red cells, FFPs and cryoprecipitate), for partial exchange transfusion 
(FFPs) and elevated INR (cryoprecipitate). 
Table 5: Outcomes associated with post-operative blood product use 
Variable PICU transfusion     
(n=67) 
No PICU transfusion 
(n=59) 
P value 
Death n(%) 4 (5.9) 0 (0.0) 0.2 




3.1 0 <0.0001 
PICU duration (days) 5.0 (3.0-11.0) 2.0 (2.0-5.0) <0.0001 
Ventilation duration 
(hours) 
47.0 (21.8-131.5) 19.9 (6.0-26.5) <0.0001 
Continuous data are median (interquartile range) 
The duration of PICU stay and mechanical ventilation was longer in the patients who received 
blood products post-cardiac surgery, compared to their counterparts who did not (both 
p<0.0001; Table 5). There was a significant difference in the standardized mortality ratio 






Table 6: Factors associated with post-operative blood product use 





Previous cardiac surgery n (%) 15 (22.4) 7 (11.9) 0.03 
Age (months) 6.4 (2.2-43.0) 31.6 (6.4-82.1) 0.003 
Weight (kg) 4.8 (3.5-13.0) 11.4 (5.6-18.2) 0.001 
Pharmacotherapy use post-
surgery n (%) 
37 (55.2) 32 (54.2) 0.9 
ACT post bypass/surgery (sec) 150.5 (131.0-174.5) 133.0 (120.0-148.0) 0.002 
Haemoglobin level at PICU 
admission (g/dl) 
13.1 (11.3-14.8) 12.4 (10.6-13.5) 0.06 
PTT level at PICU admission 
(sec) 
39.0 (29.0-50.9) 27.6 (24.5-36.0) <0.0001 
Fibrinogen level at PICU 
admission (g/l) 
1.3 (0.9-1.9) 1.5 (1.3-1.9) 0.05 
Platelet count at PICU 
admission (*10⁹/l) 
161.0 (102.0-226.0) 224.0 (160.0-269.0) 0.0006 
Continuous data are median (interquartile range) 
On univariate analysis, the children who received blood products post cardiac surgery were 
younger, smaller in size, had undergone previous cardiac surgery, and had worse clotting 
parameters as compared to their counterparts who did not receive blood products (p <0.005; 
Table 6). The use of pharmacotherapy post-surgery was similar in both the transfused and non-
transfused group of children and was not associated with a difference in post-operative blood 
product utilisation (p= 0.9).  On multiple regression analysis, no independent predictors of 
blood product use post-surgery were identified. 
Discussion  
 
This prospective observational study demonstrated an overall blood product usage prevalence 
of 53.2% in children following cardiac surgery, in line with previously published rates of 
between 14% and 79% in different contexts  (2, 5, 6). The majority of epidemiological studies 
on blood product use in children have focussed on the general PICU population, and have 
mostly described indications and outcomes associated with red blood cell usage  (1, 7). This 
study looked at all the different blood products used in the post-cardiac surgery cohort in 
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contrast with majority of previously published epidemiological studies that focussed on red 
blood cell usage. 
Cryoprecipitate was the most common blood product used in this study, demonstrating a 
difference in practice in blood product utilisation compared to studies done in North America, 
which report that red cells are the commonest blood product used among critically ill children 
and following paediatric cardiac surgery in PICUs in North America (8-11).  The main 
indications for the use of cryoprecipitate in this study was active bleeding and low fibrinogen 
level, which complies with the recommended guidelines for use of cryoprecipitate (12, 13).  
Low haemoglobin level was the indication for packed red cell transfusion in 86% of occasions 
in this study, which complied with recommendations of Lacroix and colleagues (14). On the 
contrary, data from 30 North American PICUs showed that low haemoglobin level was the 
primary indication for red cell transfusion in 17% of cases (2). Mazine and colleagues stratified 
the patients into cyanotic and acyanotic cardiac lesions, and 56% of the cohort comprising 
cyanotic congenital heart disease, with higher pre-transfusion haemoglobin levels compared to 
the acyanotic patients (mean values 11.8± 2.1 vs 11.1 ± 2.2 g/dl respectively)(2). The difference 
in the proportion of red cell transfusion due to anaemia between Mazine’s study and our study 
could possibly be because their study had a high proportion of patients with cyanotic cardiac 
lesions with generally higher haemoglobin levels, however, we did not stratify our patients into 
cyanotic and acyanotic cardiac lesions in our study.    
Carson and colleagues demonstrated a two-fold increase in odds of death for every 1g/dl drop 
in haemoglobin among adults with post-operative haemoglobin concentration below 8g/dl (15). 
Loor and colleagues described the “safety zone”, which is a U-shaped relationship between the 
deleterious effects of worsening anaemia to the left of the X-axis and aggressive interventions 
to correct anaemia to the right of the X-axis, and reported increased morbidity and mortality 
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when operating outside this “safety zone”(16). Durandy recommended the safety zone 
haemoglobin range of 8-10g/dl, based on an expert review by Loor et al(16, 17).  
Albumin was used mainly for hypotension episodes in this study. The use of albumin for 
hypotension episodes in cardiac surgery in our unit has been extrapolated from the current 
recommendations by the 2016 surviving sepsis campaign guidelines for fluid management of 
septic shock (18). The landmark Fluid Expansion as Supportive Therapy (FEAST) trial 
conducted in East Africa among children with febrile illness, compared the use of saline and 
albumin fluid boluses versus no fluid boluses for impaired perfusion, and there was reported 
similar mortality rates among the saline and albumin group(19). There is limited literature on 
the use of albumin for fluid resuscitation in paediatric cardiac surgery, however it is the policy 
in our unit to alternate ringer’s lactate and 4.5% albumin boluses for children who are clinically 
assessed as being hypovolaemic. 
Haemorrhage was the main indication (70% of patients) for the use of FFPs in this study, 
followed by deranged partial thromboplastin time. The British Committee for Standards in 
haematology recommends that FFPs should be used in bleeding patients, with caution, avoiding 
volume overload and clinical outcome should be monitored (12) . The indications for use of 
platelet concentrate in this study also complied with the current recommendation of significant 
bleeding and platelet count <100*10⁹/l following cardiopulmonary bypass surgery by the 
British Committee for Standards in haematology (12). 
The use of antifibrinolytic agent, tranexamic acid intraoperatively was similar in both the 
transfused and non-transfused group of children (p=0.9), and no patients required re-
exploration surgery due to major haemorrhage during the study period. A study by Chauhan 
and colleagues among children with cyanotic heart disease undergoing corrective heart surgery, 
randomised children into two groups and looked at the effect of tranexamic acid on post-
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operative blood loss and blood and blood product usage. The children who did not receive 
tranexamic acid intraoperatively had a re-exploration rate of 16.6% compared to 7.3% in those 
who received tranexamic acid due to high mediastinal chest tube drainage loss (p<0.05). The 
patients who received tranexamic acid had higher fibrinogen levels and reduced blood product 
usage compared to their counterparts who did not receive tranexamic acid (20).     
We observed an increase in PICU stay, ventilation duration and standardized mortality ratio 
among the children who received blood products in ICU compared to those who did not. We 
also observed that children who received blood products in theatre had a significant increase 
in PICU stay compared to those who did not. The causal relationship between blood product 
use and increased PICU stay, ventilation duration and standardized mortality ratio cannot be 
determined based on this study, as there are other possible factors that may have contributed to 
these findings such as the severity of illness related to the correction of the primary cardiac 
lesion and the complexity of the cardiac surgery, age of the blood products used, concurrent 
infections including those acquired because of being in PICU. 
 A prospective, multicentre study done by Mazine and colleagues among children transfused 
post cardiac surgery demonstrated increased PICU length of stay in the transfused group, but 
no difference in ventilation duration and mortality between the transfused and non-transfused 
children(2) . Salvin and colleagues demonstrated a significantly increased length of PICU stay 
and ventilation duration among children transfused post-cardiac surgery compared  to their 
counterparts who were not transfused(6). A large, prospective multicentre study by Bateman 
and colleagues in 30 PICUs in North America, among critically ill children reported increased 
risk of death, a higher rate of nosocomial infections, more cardiac or respiratory dysfunction, 
longer duration of mechanical ventilation and PICU stay in the transfused group compared to 
their non-transfused counterparts (21). 
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 Despotis and colleagues highlighted the “two-hit hypothesis” as an explanation for the 
transfusion-related morbidity (22). The first hit involves a primary precipitating event such as 
systemic inflammatory response syndrome (SIRS) response from surgery or the underlying 
illness, which primes the pulmonary endothelium leading to neutrophil sequestration, because 
of endothelial activation. The second hit is from the blood products used, as a result of 
biological modifiers such as human leucocyte antigen (HLA) and white cell antibodies, as well 
as neutrophil-activating mediators present in the blood products transfused, which lead to 
complement activation and pulmonary injury (22). The two-hit theory has also been 
hypothesised as an explanation for the development of transfusion-related acute lung injury, 
which is a leading cause of mortality following allogeneic blood transfusion in the United 
States (23). 
The storage lesion has also been well described as a significant factor associated with 
transfusion morbidity. Red cells undergo changes as they age under refrigerated conditions, 
resulting in an increase in free iron and pro-inflammatory markers, biochemical changes and 
loss of nitric oxide bioactivity, causing vasoconstriction and further vascular damage (24). Our 
blood bank issues pre-storage leucocyte-reduced blood for all infants as a policy, however the 
older children only get leuco-depleted blood products if specifically requested by the 
prescribing clinician. 
The factors associated with blood product use on univariate analysis in this study were previous 
cardiac surgery, younger age, smaller size and worse coagulation parameters. The previous 
cardiac surgery and worse coagulation parameters put these children at a higher risk of bleeding 
due to adhesions with prolonged re-exploration and ineffective haemostasis respectively, hence 
the need for blood products use. The multiple regression analysis however did not identify 
independent predictors of blood product use in this study. 
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Our study had strengths and limitations. The strength of this study was that the study was 
performed prospectively, therefore we could minimize information bias. The first limitation of 
this study was that it was a single centre study and therefore not generalizable to other 
populations in different contexts.  We did not measure possible confounding variables that may 
have influenced the associated outcomes we found with associated blood product use such as 
severity of illness score at admission (Paediatric Risk of Mortality; PRISM score), organ 
dysfunction score; Paediatric Logistic Organ Dysfunction (PELOD) score, storage duration of 
blood products. We do not routinely calculate scores that measure the complexity of the 
surgical repair, such as the Risk Adjustment for Congenital Heart Surgery (RACHS-1) score, 
which has a bearing on outcomes following congenital heart surgeries. Thus, we cannot 
accurately conclude the causal relationship between blood product use and our observed 
outcomes. The data collected on blood product use intra-operatively was scarce, hence a lack 




The results of our study have demonstrated a high usage of blood products in the PICU among 
children following cardiac surgery. There is a difference in blood product use practice in our 
centre, with more cryoprecipitate being used in comparison to other centres in published 
literature, that predominantly use red blood cells. Children who received blood products 
following cardiac surgery had a longer duration of PICU stay, mechanical ventilation and a 
higher standardized mortality ratio, compared to their counterparts who did not. The results of 
this study can be used to guide the use of blood products in paediatric cardiac surgery at our 
centre, however they may not be generalizable in other centres. Larger multi-centre studies will 
be needed in the future to analyse the relationship between intra-operative factors and 
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utilization of blood products post cardiac surgery and generate results that can be generalised 
to develop protocols for the use of blood products in paediatric cardiac surgery.  
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Appendix 1: Protocol 
 
TRANSFUSION PRACTICES AMONG CHILDREN UNDERGOING CARDIAC 
SURGERY ADMITTED TO THE RED CROSS WAR MEMORIAL CHILDREN’S 
HOSPITAL PAEDIATRIC INTENSIVE CARE UNIT 
STUDENT: DR KAISER FITZWANGA (FTZKAI002) 
COURSE: MASTER OF PHILOSOPHY IN PAEDIATRIC CRITICAL CARE 
SUPERVISORS: DR S SALIE, PROF A ARGENT, PROF B MORROW 
 
Background 
Blood products are frequently given to patients undergoing cardiac surgery. Recently there has 
been increasing focus on the complications associated with blood transfusion.  Some of those 
complications relate primarily to the volumes of blood used, but many relate to the blood 
products themselves(1, 2). The initial focus of adverse event review was on issues such as 
compatibility, infection (bacterial and increasingly viral). However, there is now increasing 
focus on the associations between use of blood products and respiratory problems, duration of 
paediatric intensive care unit (PICU) stay, morbidity and mortality(1, 2). There are new 
recommendations for the use of blood products in the perioperative period for children 
undergoing cardiac surgery, and the focus of this study is really on defining the transfusion 
practice in our unit(3, 4).  This would provide the basis for further focus on quality 
improvement and optimization of protocols. 
Blood products are not identical across the world and may vary considerably in how they are 
collected, stored, processed and administered. The quality of blood products is hugely variable 
in different parts of the world. The guidelines for blood transfusion in the cardiac perioperative 
period are based on relatively small numbers of studies. 
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In South Africa, donated blood is collected and stored in a solution containing sodium citrate 
as the anticoagulant. Red cells are preserved and stored at a temperature of 1°- 6°C for a 
duration of up to 42 days, fresh frozen plasma (FFP) is separated from anticoagulated whole 
blood within 18 hours of donation, frozen and stored at a temperature of < -18°C. Platelets are 
prepared from the buffy layers of whole blood donation within 8 hours of donation and stored 
at a temperature of 22°C for a duration of 5 days. Cryoprecipitate is prepared from FFP by 
thawing FFP at temperatures of 0-4° C, and then the cold fraction is stored at temperatures < -
18° C for a duration of up to 1 year. (South African National Blood Service). 
Risk Factors Associated With Transfusion Or Bleeding During Or After Cardiac Surgery 
The factors that predispose patients undergoing cardiac surgery to bleeding include patient, 
procedure and drug-related factors. Patient related factors include age, preoperative anaemia, 
preoperative thrombocytopenia, preoperative coagulopathy and antithrombotic therapy. 
Procedure related factors include repeated procedures (re-operation), the type and urgency of 
the operation, cardiopulmonary bypass (CPB); the use of heparin on CPB, residual heparin, 
reduced thrombin generation, fibrinogen deficiency, thrombocytopenia, platelet dysfunction, 
hyperfibrinolysis, hypothermia, acidosis during the procedure, dilution of clotting factors with 
intravenous fluid administration, surgical causes and consumption of clotting factors in active 
bleeding(5-7). 
Drug related factors are related to use of antiplatelet agents such as aspirin, clopidogrel or use 
of anticoagulant therapy such as warfarin, or use of low molecular weight heparin or 
unfractionated heparin (7). 
The interventions that have been shown to reduce bleeding during cardiac surgery include: 
anti-fibrinolytic therapy such as tranexamic acid, recombinant factor VIIa and epsilon 
aminocaproic acid, use of minimized CPB circuits with reduced priming volume, 
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normovolaemic haemodilution, salvage of blood from the CPB circuit, modified ultrafiltration, 
and microplegia(8-11). The use of pre-operative erythropoietin increases the haemoglobin 
level prior to surgery, hence reducing blood transfusion requirement. 
Refrigerated stored blood undergoes biochemical and biophysiologic changes that include 
changes in rheology and shape, cellular metabolism, oxidative stress and changes induced from 
the additive solution (12). There are discrepancies in the evidence in paediatric studies looking 
at the association between the effects of transfused stored blood and post cardiac surgery 
morbidity and mortality. Some of the studies have shown no difference in mortality and 
morbidity with transfusion of old versus fresh blood, while other studies have described 
increased bleeding risk, mortality and morbidity with use of old blood (13-16). There are six 
large RCTs ongoing currently, to look at the effects of transfusion of stored versus fresh blood 
on the development of multiorgan dysfunction syndrome (MODS) and mortality in children 
and adults in USA, Canada, Finland, New Zealand and Australia. 
Type Of Blood Products Used And Indications In Cardiac Surgery 
Multiple factors need to be taken into account before transfusion of red blood cells in cardiac 
surgery. The use of haemoglobin level in isolation, as a threshold for red cell transfusion is not 
sufficient, and additional factors such as markers of oxygen delivery, ongoing bleeding and 
cormobid disease processes should be considerations factored in the decision to transfuse red 
blood cells (4). 
Red blood cells increase arterial oxygen content by increasing haemoglobin level, therefore 
increasing tissue oxygen delivery. However, this does not take immediate effect as red cell 
transfusion increases blood viscosity which can reduce cardiac output in normovolaemic 
patients whose cardiac function is not impaired. Stored red cells undergo biochemical and 
biophysiologic changes which affects their oxygen affinity and delivery (12). 
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Transfusion in neonates and young children is most likely to be equivalent to a massive 
transfusion leading to dilution of clotting factors(17). Massive transfusion is defined as a 
situation in which transfusion needs result in replacement of 80 ml/kg in 24 hours, or 40 ml/kg 
in 3 hours or blood loss of 2-3 ml/kg/min (18). Fresh frozen plasma is a source of procoagulant 
factors and fibrinogen, and is indicated in the context of massive bleeding, where it is 
administered in fixed ratios with platelets and red cells (19, 20). Cryoprecipitate contains high 
concentrations of factors VIII,XIII and fibrinogen, and is indicated for correcting 
hypofibrinogenemia at levels below 1g litre¯¹(21). 
Platelet transfusion is indicated in significant microvascular bleeding with diffuse oozing 
without an obvious surgical cause, after correction of clotting factors(5, 22). Platelet 
dysfunction and thrombocytopaenia increase the risk of bleeding and threshhold for transfusion 
after CPB(23). The factors that influence platelet count and function during CPB include 
exposure to the bypass circuit and shear stress at different levels of CPB resulting in platelet 
adhesion and aggregation, inflammatory mediators during CPB, haemodilution, hypothermia, 
preoperative use of anti-platelet agents(5, 7, 24, 25). Other molecular mechanisms that 
contribute to platelet dysfunction include loss of cell surface glycoprotein receptors, such as 
the platelet collagen receptor, glycoprotein GPIb-IX and GPIIb-IIIa (5, 23).  
Transfusion Practice And Threshholds Used In Paediatric Cardiac Critical Care 
The physiologic threshold at which oxygen consumption decreases due to reduced oxygen 
delivery in humans is a haemoglobin level of 3-4 g/dl, an oxygen extraction ratio of 0.44 and 
a mixed venous oxygen of 34 mmHg as demonstrated in studies in Jehovah’s witness 
population who decline blood transfusion(26). The evidence guiding red cell transfusion 
threshholds in children is scanty . Data obtained from retrospective studies in Kenyan children 
with severe anemia related to high parasitemia from P.Falciparum malaria demonstrated high 
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early mortality rates at haemoglobin levels below 4g/dl(27).  Carson and colleagues 
demonstrated a > 50% mortality rate of  in patients with a post operative haemoglobin below 
levels of 5 g/dl, as well as a two-fold increase in odds of death for every 1g/dl drop in 
haemoglobin among adults with post-operative haemoglobin concentration below 8g/dl (28).  
Patients with ongoing bleeding, who are in haemorrhagic shock should receive red blood cells, 
with plasma and platelet concentrate in fixed ratios (4). Results from the subanalysis of the 
Transfusion Requirements in Paediatric Intensive Care Unit (TRIPICU) study suggest that a 
haemoglobin threshhold of 7g/dl  and 9 g/dl for haemodynamically stable children >28 days 
old with non cyanotic heart disease and  cyanotic heart disease respectively  is reasonable. 
These threshholds have been adapted for use in children post cardiac surgery (3, 4, 8). 
The British Committee for standards in haematology recommends that fresh frozen plasma 
(FFP) and cryoprecipitate should not be used primarily on the basis of abnormal lab results, 
but should be restricted to use in patients with signs of bleeding or planned invasive procedures 
(18). FFP should be given to children with prothrombin time/ activated partial thromboplastin 
time (PT/APTT) levels >1.5 times the midpoint of the normal range and cryoprecipitate for 
fibrinogen levels <1.5g/l associated with significant haemorrhage following cardiopulmonary 
bypass (18). Platelets should be transfused when there is clinically significant haemorrage and 
a threshold of < 100*10⁹/l should be used in paediatric cardiac surgery (18). 
Complications Associated With Blood Product Use 
In general, PICU patients who receive blood products have a worse outcome than those who 
are not transfused (1). 
Blood product transfusion is associated with immune-mediated and non immune-mediated 
risks. Immune-mediated risks include transfusion-related lung injury, acute haemolytic 
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reactions, allergic and anaphylactic reactions, non haemolytic febrile reactions, and transfusion 
associated graft versus host disease(6, 29). Non-immune mediated risks of blood transfusion 
include hyperkalaemia, fluid overload, transmission of infection, hypothermia and iron 
overload (29). 
The presence of leucocytes in blood has been linked to the febrile reactions and immune-
mediated reactions observed after blood transfusion, therefore leucoreduction and filtration is 
perfomed in most centres prior to blood storage (30-32). Leukoreduction has been further 
shown to increase packed red cell viability prior to storage(30). Although transfusion-
associated graft versus host disease (TA-GVHD) is an uncommon complication of blood 
transfusion, it is a fatal complication especially for patients with congenital immune deficiency, 
therefore gamma-irradiation of blood products prior to transfusion impairs the proliferation of 
lymphocytes, and prevents TA-GVHD (30, 32). 
High income countries which are also quite well resourced, have adopted a universal policy of 
leucocyte depletion of stored blood products, which is a costly affair that low and middle-
income countries may not afford routinely. In South Africa, infants routinely receive 
leucodepleted bood as a standard, and the blood packs are leucodepleted during preparation 
and storage. Adult units are generally used to prime the bypass circuit for infants undergoing 
cardiac surgery. The adult blood packs are not routinely leucodepleted, unless there is a clinical 
indication to warrant the use of leucocyte depleted blood products, in this case the clinician 
will put in a specific request to the blood bank for leucocyte depleted blood (33, 34).  
Bacterial infections that occur post transfusion may happen because of bacterial contamination 
of blood products. This is because of bacterial contamination during venipuncture or collection 
of blood from an asymptomatic bacteremic donor. The symptoms of bacterial infection as a 
result of transfusion can occur during or immediately after transfusion of a contaminated blood 
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product bag, and include fever, rigors, erythema and cardiovascular collapse(29). Gram 
negative bacteria such as Yersinia entercolitica and Pseudomonas rapidly proliferate at storage 
temperatures of 4°C, whereas gram positive bacteria such as Staphylococcus epidermidis, 
Staphylococcus aureus and Bacillus species proliferate rapidly at room temperature(29).  
In the well-resourced countries, donor blood is routinely screened for hepatitis B and C, HIV 
1 and 2, CMV and human T cell lymphotropic virus, the incidence of viral transmission through 
blood transfusion has greatly reduced(29, 31, 35). Donor blood is also routinely screened for 
Syphilis. In South Africa, donor blood is routinely screened for hepatitis B and C, HIV 1 and 
2, and Syphillis. (South African National Blood Service) The variant Creudzfeldt-Jakob 
disease is a human prion disease that can also be transmitted by contaminated blood products 
(29, 35). The following are agents that can also be transmitted by transmission of contaminated 
blood, however they are not routinely screened in donor blood; hepatitis A virus, parvo B19 
virus, Babesia leishmania, plasmodium, and Brucella species(35). 
Transfusion of blood products (red cells, fresh frozen plasma, platelet concentrate) intra and 
post operatively has also been found to be a potential risk factor to development of health care 
associated infections in cardiac surgery(36-38). 
Several studies have been done and demonstrated an association between red cell transfusion 
and length of stay in post-operative paediatric cardiac patients (39-42). The impact of changing 
transfusion practices in paediatric cardiac critical care has also been shown to have an effect in 
morbidity post cardiac surgery and reduced hospital costs (43, 44). Use of lower haemoglobin 
thresholds for red cells transfusion and leucocyte reduced blood products are factors that have 
been shown to reduce morbidity related to paediatric cardiac surgery (43, 45). 
The morbidity related to blood product use in paediatric cardiac surgery is as a consequence of 
immune and non-immune mediated mechanisms(31). Transfusion-mediated immune 
suppression has been described in transfusion medicine and thought to pose an increased risk 
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in postoperative infections and activation of latent viral infections. It is thought that these 
effects are a result of the donor leucocytes in transfused blood which express class I and class 
II Human leucocyte antigens (29, 31, 46). 
Complications such as transfusion related lung injury (TRALI), transfusion- associated cardiac 
overload, nosocomial infections, multi-organ organ dysfunction will result in increased 
ventilator days and hence increased PICU length of stay and have also been in implicated in 
associated mortality (31, 35, 47, 48). 
Study Objectives 
Primary Objectives: 
1. To describe the use of blood products in the 72 hour period following cardiac surgery 
in children at the Red Cross War Memorial Children’s Hospital 
2. To describe the indications for blood product use in children post cardiac surgery used 
by clinicians 
Secondary Objectives: 
     1. To describe the outcomes associated with post-operative blood product use (ventilator          
hours, PICU length of stay, PICU mortality)  
      2. To describe the  factors associated with post-operative blood product use 
Methodology 
Study design 






The study population will comprise all children under 18 years of age who are admitted to the 
Red Cross War Memorial Children’s Hospital (RCWMCH) paediatric intensive care unit 
(PICU) following cardiac surgery during the study period. 
Exclusion criteria 
Children admitted to PICU with other medical and surgical conditions other than cardiac 
surgery   
Recruitment and enrollment 
The patients will be recruited consecutively into the study upon admission to the PICU post 
cardiac surgery and will be identified by study numbers on the case record form (CRF). Consent 
for cardiac surgery  and use of blood products is routinely taken by the cardiac surgical team , 
however, additional verbal consent will be taken by the cardiothoracic surgeon from the 
parents/guardians, to give permission for the routinely recorded data regarding the patient’s 
surgery to be used for the purpose of this study. The parents/guardians will be informed that 
they have an option to “opt out”, should they feel uncomfortable with the study clinician using 
data about their children’s surgery for the purpose of this study. This will not compromise the 
care offered to their children while admitted to the intensive care unit in any way. 
Data collection methods 
The study data will be obtained from blood bank records, intra operative charts and patient 
folders (including PICU observation charts). The definition of blood products includes the 
following; red blood cells, fresh frozen plasma, platelets, cryoprecipitate and human albumin. 
Variables which will be obtained from blood bank records includes type and characteristics of 
the different blood products used. The intra operative charts will provide the following 
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information: preoperative cardiac diagnosis, surgical procedure performed, the type, 
characteristics, age and volumes of different blood products used, haemoglobin level pre and 
post surgery, details on CPB and details of the use of pharmacotherapy to prevent bleeding. 
Demographic data will be obtained from the patient folders, and includes; age, sex, weight, 
date of PICU admission and discharge. Additional information which will be obtained from 
the patient folders (including the PICU observation charts) includes the following; 
haemoglobin levels, oxygen saturations, clotting screen, chest drain losses, duration of 
mechanical ventilation, length of stay and mortality (including PIM 3 scores) in the PICU, 
previous cardiac surgery, previous blood transfusion, previous PICU admission. The 
investigator will provide a form ( Appendix 2) to be filled by the PICU clinician, indicating the 
blood products used, quantities and indications for transfusion of blood products. Chest drain 
losses will be recorded for the 72 hours post cardiac surgery. Data will be collected on 
transfusion of each blood product used per patient over a period of 72 hrs post cardiac surgery. 
The data obtained will then be entered in a standardised CRF (Appendix 2). Data will be 
collected prospectively over a 6 month period. 
Data analysis 
The data collected will be entered into an excel spread sheet and exported to and analysed using 
Statistica (version 13, StatSoft Inc, USA). Continuous variables will be expressed as a mean ( 
±standard deviation) or median( ±inter-quartile range). Categorical variables will be expressed 
as a frequency percentage (%). Primary outcome measures will be the blood product use and 
indications of blood products used in children admitted to the PICU after cardiac surgery. The 
secondary outcome measures will be the total ventilation hours, PICU length of stay, mortality 






This is a minimal- risk observational study of routinely collected data related to standard 
clinical practice. No study- related interventions or investigations will be performed.  
Potential Benefits 
Patients will not directly benefit from study participation. The results of the study will be used 
to measure current practices involving the use of blood products in children undergoing cardiac 
surgery. Findings could form the baseline for future studies and inform practice- improvement 
initiatives. The study therefore has potential societal benefit, and although individual 
participants do not stand to benefit, there is the potential for improved practice and outcomes 
for future children admitted for cardiac surgery. 
Vulnerability 
This is a particularly vulnerable population of critically ill infants and children following 
cardiac surgical procedures. However, this study does not impose any additional risk to 
participants beyond that of standard PICU care. The study could not be done on a less 
vulnerable group, given the particular pathophysiology of postoperative children with 
congential cardiac disease. 
Privacy And Confidentiality 
Information obtained from the study will be kept confidential by recording data in 
questionnares with assigned study numbers, avoiding the use of patient names. Hard copies 




Indepent Review And Ethical Compliance 
The study will be undertaken after approval from the  Department of Paediatrics and Child 
Departmental Research Committee (DRC) and the University of Cape Town’s Faculty of 
health Sciences Human Research Ethics Committee (HREC), and carried out as guided by the 
Declaration of Helsinki, 2013, Ethical Principles for Medical Research involving Human 
Subjects. Furthermore, permission will be sought from the hospital medical superintendant 
before the study is commenced. 
Informed Consent 
On admission to the PICU parents/guardians are given a pamphlet describing the PICU, and 
stating that during their child’s stay routine information may be collected for research purposes, 
but that no research will be done that impacts on their child’s experience or treatment in PICU. 
The parents/guardians will be verbally provided an “opt-out” option should they feel 
uncomfortable with this process. We believe this process respects parental autonomy, in 
addition, they will not be penalised in any way for choosing to “opt-out”. 
We request a waiver of the need for full informed consent given that: 
1) This is a purely observational study of routinely collected data, and will not affect 
patient care or the experience the child has in PICU in any way; 
2) Parents/legal guardians may be situationally incapacitated by the stress and trauma of 
their child undergoing serious invasive surgical procedures and the subsequent 
admission to the daunting technological environment of the PICU, and therefore unable 
to fully understand the request for research involvement;(49) 
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3) Parents/legal guardians will already have signed consent for the surgery, and potentially 
for receipt of blood products, investigations, placement of lines etc. Another form to 
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Appendix 2: Case Record Form 
 
TRANSFUSION PRACTICES AMONG CHILDREN POST CARDIAC SURGERY 
ADMITTED TO RCWMCH PICU STUDY BY DR KAISER FITZWANGA 
 
SECTION A: PATIENT DEMOGRAPHICS 
 
Folder No:                                         Date of birth:                                    Study Number :                        
Sex: Male:          Female:           Weight(kg) :                     
Date of PICU admission:                                     Date of ICU discharge:  
PIM 3 score at admission:  
 
SECTION B: PERI OPERATIVE CHECKLIST 
1.Recent admission to PICU within 14 days prior to cardiac surgery: Yes          No  
2.Currently admitted to PICU at the time of cardiac operation: Yes           No   
3.Recent mechanical ventilation within 14 days prior to cardiac surgery: Yes          No   
4.Currently mechanically ventilated in the PICU at the time of the cardiac operation:Yes           
No   
5.Previous cardiac surgery prior to the current cardiac operation: Yes          No   
If Yes, please select all that applies by placing check mark in the box: 
Median sternotomy                 Lateral thoracotomy                Other: 
6.Recent blood transfusion prior to current cardiac surgery: Yes           No           
 
SECTION C: INTRA OPERATIVE CHECKLIST 
7.Preoperative cardiac diagnosis: (Please select by placing a check mark in the box) 
VSD                                              HLHS                                      AS    
ASD                                              TAPVC                                   TR   
AVSD                                           PAPVC                                    Interrupted Aortic arch   
                            
 
dd/mm/yyyy      
                     
   
   













TET                                               MR                                          Aortopulmonary window  
TA                                                 AR                                           Cotriatrum 
TGA                                              PA                                            PDA    
DORV                                           MS                                           ALCAPA        
Other: 
8.Surgical procedure done: (Please select by placing a check mark in the box)  
VSD closure                                        TV annuloplasty                         Arterial switch      
ASD closure                                        AV repair                                   TAPVC repair   
Total correction of  TET                     AV replacement                         PAPAVC repair  
MV repair                                            Pulmonary valvuloplasty           Aortic arch repair  
MV replacement                                  Glenn shunt procedure              Norwood procedure                 
Ross procedure                                    Fontan procedure                       PDA ligation      
Sub aortic ridge resection                    Central shunt procedure             ALCAPA repair   
Konno procedure                                 BT shunt procedure                    RVOT patch  
Other: 
9.Use of blood products during surgery and/ on bypass:  Yes           No   
10.Blood products used during surgery and/on bypass: (Please select all that applies by 
placing a check mark in the box) 
Packed red blood cells          
Whole blood             
Fresh frozen plasma              
Platelet concentrate                 
Cryoprecipitate                      
Albumin                                 
11.Use of colloids intraoperatively: Yes         No    
12.Characteristics of blood products used. (Please select all that applies by placing check 
mark in the box) 
Irradiated      Yes               No  
 
   
   
  
  
   
   
   
   







































Leucocyte depleted    Yes           No     
Washed cells   Yes             No    
Emergency O- negative blood  Yes           No         
Cell saved blood Yes           No         
Pump blood Yes          No   
13.Haemoglobin level post cardiac surgery and/ or bypass (g/dl):              
14.ACT before bypass ( seconds):  
15.ACT after bypass ( seconds):  
16.Pharmacotherapy used to prevent bleeding post cardiac surgery and/ or bypass: Yes          
No  
 If Yes, please select all that applies by pacing check mark in the box: 
Aprotinin              Activated factor VII           Tranexamic acid              Desmopressin          
Other:  
17.Underwent repeat bypass in the OR: Yes            No                                         
 
SECTION D: ICU ADMISSION CHECKLIST 
18.Haemoglobin level at admission (g/dl):  
19.Clotting screen at admission:  
PTT (s)               Fibrinogen (g/l)               Platelet count (*10⁹/l)  
20.Received mechanical ventilation: Yes         No          
21. Date and time of initiation of mechanical ventilation:  
22. Date and time of extubation:                                                      
23.Re intubated within current post-operative period: Yes          No        
If Yes, in Q23, go to Q24. If No, skip and go to Q26 
24. Date and time of re intubation:  
25. Date and time of extubation after re intubation: 




    
  
 
   
 
  






dd/mm/yyyy,  hr:min 
dd/mm/yyyy, hr:min 
  
      







27.Underwent re do surgery: Yes          No  
28.Blood product use in PICU: Yes           No  
29.Chest drain losses post cardiac surgery(ml/kg/hr):  
6 hours post-op                                  24 hours post-op                   72 hours post-op  
12 hours post-op                                48 hours post-op   
30.Blood products transfused in PICU: (Please select all that applies by placing a check 
mark in the box) 
Packed red blood cells         Volume transfused (ml/kg)   
Whole blood                        Volume transfused (ml/kg)         
Fresh frozen plasma            Volume transfused (ml/kg)   
Platelet concentrate             Volume transfused (ml/kg)   
Cryoprecipitate                    Volume transfused (ml/kg)    
Albumin                               Volume transfused (ml/kg) 
31. Characteristics of blood products used. (Please select all that applies by placing check 
mark in the box) 
Irradiated  Yes            No   
Leucocyte depleted  Yes             No    
Washed cells Yes             No      
Emergency O- negative blood  Yes            No         
Cell saved blood Yes           No         
Pump blood Yes          No  
32.Indications for blood product use in PICU (Will refer to a separate form  filled by 
prescribing doctor) 
33.Pharmacotherapy used to control bleeding in PICU: Yes          No  
If Yes, please select all that applies by placing check mark in the box: 
Tranexamic acid        Activated factor VII         Vitamin K           Other: 
34.Mortality in PICU:  Yes           No          If Yes, date of death:  
























     
  
  




INDICATIONS FOR BLOOD PRODUCT USE IN POST OPERATIVE CARDIAC 
PATIENTS (To be filled by the prescribing doctor at the bed side for each transfusion 








1.Red blood cells (Please select the type prescribed): Whole blood          Packed red cells   
Bleeding: Yes          No  
If yes, please indicate the chest drain loss threshold used in ml/kg/hr: 
Low haemoglobin level: Yes         No  
If yes, please indicate the haemoglobin threshhold used in g/dl: 
Hypotension episodes: Yes         No   
(Hypotension will be defined as the systolic blood pressure or mean blood pressure 
(mmHg) below the low limit as set by the intensivist) 
Hypoxemia: Yes            No         
(Hypoxemia will be defined as oxygen saturation below the low limit as set by the 
intensivist) 
Consultant orders: Yes           No   
Other indications by prescribing doctor:   
Volume prescribed (ml/kg):  
 
2. Fresh frozen plasma 
Bleeding: Yes           No    

















Partial prothrombin time level: Yes           No   
If yes, please indicate the PTT(s) threshold level used: <*2 PTT control         >*2 PTT 
control 
Hypotension episodes: Yes          No 
(Hypotension will be defined as the systolic blood pressure or mean blood pressure 
(mmHg) below the low limit as set by the intensivist) 
Consultant orders: Yes          No   
Other   indications by prescribing doctor: 
Volume prescibed (ml/kg):   
 
3. Platelet concentrate  
Bleeding: Yes          No   
If yes, please indicate the chest drain loss  threshold used in ml/kg/hr:  
Low platelet count: Yes          No   
If yes, indicate the platelet count threshhold used(*10⁹/l):  
Hypotension episodes: Yes           No  
(Hypotension will be defined as the systolic blood pressure or mean blood pressure 
(mmHg) below the low limit as set by the intensivist) 
Consultant orders: Yes           No   
Other indications by prescribing doctor:    
Volume prescribed (ml/kg):  
 
4.Cryoprecipitate 
Bleeding: Yes          No    
If yes, please indicate the chest drain loss threshold used in ml/kg/hr:  
Low fibrinogen level: Yes          No   
If yes, please indicate the threshhold level(g/l) used:  




















(Hypotension will be defined as the systolic blood pressure or mean blood pressure(mmHg) 
below the low limit as set by the intensivist) 
Consultant orders: Yes            No   
Other indications by prescribing doctor: 
Volume prescribed (units):  
 
5.Albumin 
Hypotension episodes:  Yes          No          
(Hypotension will be defined as the systolic blood pressure or mean blood pressure 
(mmHg) below the low limit as set by the intensivist) 
Consultant orders: Yes            No              
Other indications by prescribing doctor: 
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